Drug Target Review Assays ebook 2022
In this ebook, you can find articles on the development of novel assays and technology - download now for free!
List view / Grid view
In this ebook, you can find articles on the development of novel assays and technology - download now for free!
A new study from Niigata University has found a binding protein that is vital for proper development of the central nervous system.
A new study on substance abuse disorders highlights an existing connection between specific neurons and peripheral organs.
New research by the Salk Institute has shown cellular rejuvenation therapy safely reverses signs of ageing in mice.
Scientists have gained deeper knowledge about the mislocalisation of a protein, providing a possible therapeutic target that could have implications in treating dementia.
A study has shown how Parkinson’s disease may be driven by cell stress-related biochemical events that disrupt a key cellular clean-up system.
Research from the University of Copenhagen reveals how Deep Brain Stimulation treatment of walking problems in Parkinson’s disease could be optimised by targeting specific neurons in the brainstem.
In a scientific first, researchers have discovered fundamental mechanisms by which the hippocampus region of the brain organises memories into sequences and how this can be used to plan future behaviour.
Representing a breakthrough in better understanding how tau proteins cause neurodegenerative disease, scientists have mapped the tau interactome.
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
Researchers used advanced microscopy and proteomics to unveil new findings on Huntington's disease and open avenues to future treatments.
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.